Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
661-680 of 1,738 trials

Advanced Solid Tumors: Datopotamab Deruxtecan Study

We are studying a new treatment for patients with advanced or metastatic solid tumors to see how well it works and its safety when used alone or with other cancer drugs.

Various Types of CancerEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Frontotemporal Dementia: AVB-101 Treatment Study

We are testing a new treatment called AVB-101 for individuals with frontotemporal dementia due to specific genetic mutations. The study aims to assess its safety and early effects on symptoms.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Type 1 Diabetes: Sotagliflozin for Kidney Health

We are investigating whether sotagliflozin can improve kidney oxygen levels in people with type 1 diabetes and chronic kidney disease. This study aims to understand its effects over three months of treatment.

Type 1 Diabetes with Kidney Complications6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInternal MedicineNephrology

Volrustomig for Advanced Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of volrustomig combined with chemotherapy and other drugs for patients with advanced or metastatic non-small cell lung cancer. This research aims to find better treatment options for this condition.

Non-small Cell Lung CancerSolid TumorsSQ, NSQ NSCLCEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cancer Treatment: PET Tracers and T Cell Activity

We are studying how two PET tracers relate to T cell changes in cancer patients before surgery. This research may help us understand T cell activation and its impact on tumor response.

Breast CancerEsophageal CancerMelanoma3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Solid Tumors: Atezolizumab with EIK10001 and Radiation

We are studying a new treatment combining atezolizumab, EIK10001, and radiation for patients with advanced solid tumors like pancreatic cancer and triple-negative breast cancer. This trial aims to evaluate how well this combination works in controlling cancer.

Metastatic Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Advanced Sarcomas: Pembrolizumab and Cabozantinib Study

We are investigating the effects of a combination of pembrolizumab and cabozantinib in patients with advanced sarcomas. The goal is to see if this treatment can help prevent disease progression and improve overall outcomes.

Advanced Metastatic Sarcomas>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Sarcoma: Bintrafusp Alfa and Doxorubicin

We are studying a new treatment combining Bintrafusp alfa with doxorubicin for patients with advanced sarcoma. The goal is to see if this combination improves tumor response and safety compared to standard treatments.

Soft-Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Colorectal Cancer: RO7198457 Treatment Study

We are comparing a new treatment called RO7198457 to watchful waiting in patients with high-risk, resected Stage II and Stage III colorectal cancer. The goal is to see if the new treatment can help prevent cancer recurrence better than simply monitoring.

Stage II/Stage III Rectal Cancer or Stage II (High Risk)/Stage III Colon Cancer>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Tardive Dyskinesia: Safety Study of ADE513

We are testing a new medication for people with moderate to severe tardive dyskinesia to see how safe it is for long-term use. The study will also look at its long-term effects on managing symptoms.

Tardive Dyskinesia1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry

Melanoma: [68Ga]Ga-FAPI PET/CT Imaging Study

We are testing a new imaging method to see how well immune checkpoint inhibitor therapy works in patients with advanced melanoma. This study aims to improve response evaluation during treatment.

Malignant Melanoma6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesDermatologyOncology

HER2+ Cancer Treatment: Zongertinib Study

We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.

Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaMetastatic Breast CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Dostarlimab for Untreated Locally Advanced Rectal Cancer

We are studying the effects of dostarlimab in patients with untreated Stage II/III dMMR/MSI-H rectal cancer. The goal is to see how well it works and how safe it is for these individuals.

Rectal CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Pleural Mesothelioma: Pembrolizumab with Chemotherapy

We are studying a combination of pembrolizumab and standard chemotherapy for patients with resectable epithelioid and biphasic pleural mesothelioma. The goal is to see if this treatment improves response rates and overall survival.

Malignant Pleural Mesothelioma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

MEPENDAX: Axitinib and Etoposide for Pediatric Brain Tumors

We are studying a new treatment combining axitinib and oral etoposide for children and young adults with relapsing medulloblastoma or ependymoma. The goal is to find the safest dose and see if it helps improve survival.

MedulloblastomaEpendymoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

HIV and Hepatitis B: Bepirovirsen Treatment Study

We are studying a new treatment for people living with both HIV and chronic Hepatitis B. The trial aims to see if bepirovirsen can help reduce the Hepatitis B virus in patients already receiving antiretroviral therapy.

Hepatitis B1-2 yearsEfficacy phase (II)Investigational MedicinesInfectious DiseasesInternal Medicine

Alzheimer's Disease: Efavirenz Study

We are investigating whether Efavirenz can affect certain biomarkers in people with early Alzheimer's Disease. This study aims to understand its safety and how it works in the body.

Alzheimer's Disease3-6 monthsSafety phase (I)Efficacy phase (II)Standard MedicinesNeurology

Peyronie's Disease: Study of Bacterial Collagenase

We are testing a new bacterial collagenase injection for men with Peyronie's Disease to see if it improves penile curvature and reduces discomfort. The study will assess both safety and effectiveness of this treatment.

Peyronie's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesUrology

Extensive-Stage Small Cell Lung Cancer: I-DXd with Atezolizumab

We are studying a new treatment combining I-DXd and atezolizumab, with or without carboplatin, for patients with extensive-stage small cell lung cancer. The trial aims to assess safety and effectiveness as a first-line treatment.

Extensive-stage Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Recurrent or Metastatic Solid Tumors: I-DXd Treatment Study

We are testing a new treatment called I-DXd for patients with recurrent or metastatic solid tumors. The study aims to see how well it works and how safe it is for participants.

Recurrent or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology